Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | SVP Chief Commercial Officer | February 21, 2023 | February 24, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
STANDARD BIOTOOLS INC.
Report date February 21, 2023 · Filed February 24, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,657 |
Ending reported balance
After 2023-02-21 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-21 · Exercise / conversion · Acquired 20,833 · Balance 20,833 Row 2 · 2023-02-21 · Tax withholding · Disposed 6,176 · Balance 14,657 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 229,167 |
Reported balance
After 2023-02-21 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-02-21 · Exercise / conversion · Disposed 20,833 · Balance 229,167 F1: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock. F2: On December 20, 2022, the Reporting Person was granted 250,000 Restricted Stock Units vesting in quarterly installments over the course of three years commencing February 20, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock.
F2: On December 20, 2022, the Reporting Person was granted 250,000 Restricted Stock Units vesting in quarterly installments over the course of three years commencing February 20, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2023 Filed Feb 24, 2023 02:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Exercise / conversionRestricted Stock Units · Derivative | 20,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-23-000010 · wf-form4_167720668432890.xml · derivative · entry 3 Davis Jeremy Steven · CIK 0001919871 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 229,167 Underlying: Common Stock · 20,833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock. F2 · derivative.exercise_date: On December 20, 2022, the Reporting Person was granted 250,000 Restricted Stock Units vesting in quarterly installments over the course of three years commencing February 20, 2023. F2 · derivative.expiration_date: On December 20, 2022, the Reporting Person was granted 250,000 Restricted Stock Units vesting in quarterly installments over the course of three years commencing February 20, 2023. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 02:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Tax withholdingCommon Stock | 6,176 | $2.03 | $12,537.28 |
DisclosureSEC source: 0001162194-23-000010 · wf-form4_167720668432890.xml · nonDerivative · entry 2 Davis Jeremy Steven · CIK 0001919871 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,657 Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 02:45 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Exercise / conversionCommon Stock | 20,833 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-23-000010 · wf-form4_167720668432890.xml · nonDerivative · entry 1 Davis Jeremy Steven · CIK 0001919871 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 20, 2022 Filed Jan 20, 2023 22:24 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantRestricted Stock Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-23-000002 · wf-form4_167425346769614.xml · derivative · entry 1 Davis Jeremy Steven · CIK 0001919871 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of LAB common stock. F2 · derivative.exercise_date: The restricted stock units vest in quarterly installments over the course of four years commencing February 20, 2023. F2 · derivative.expiration_date: The restricted stock units vest in quarterly installments over the course of four years commencing February 20, 2023. Read SEC document |
| April 20, 2022 Filed Apr 21, 2022 22:21 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantRestricted Stock Units · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001162194-22-000047 · wf-form4_165057963638945.xml · derivative · entry 1 Davis Jeremy Steven · CIK 0001919871 · SVP Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of LAB common stock. F2 · derivative.exercise_date: Restricted Stock Units vest as to 1/4th of the underlying shares on May 20, 2023, and as to an additional 1/16th of the total number of shares each quarter thereafter. F2 · derivative.expiration_date: Restricted Stock Units vest as to 1/4th of the underlying shares on May 20, 2023, and as to an additional 1/16th of the total number of shares each quarter thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.